The Challenge of Silent Pathogens

The recent investigation into KPC-2 CPE transmission in a South Korean hospital highlights the critical role of genomic surveillance in modern healthcare. Carbapenemase-producing Enterobacterales (CPE) represent a significant threat to patient safety worldwide. During a three-month outbreak in 2019, clinicians identified 42 cases of KPC-2-producing bacteria. Although the outbreak subsided after strict intervention, researchers used retrospective genomic analysis to uncover how the bacteria actually spread. Consequently, they found that transmission began an entire month before the hospital detected the first official case.

Advanced tools like whole-genome sequencing (WGS) provide insights that traditional epidemiological tracing often misses. In this study, the majority of cases involved Klebsiella pneumoniae ST307. By analyzing single nucleotide polymorphisms (SNPs), the team identified three distinct clades. One clade was strictly limited to a specific ward, while another moved between units via a hemodialysis center. These findings suggest that unrecognized links, such as shared healthcare personnel or common treatment areas, often facilitate the silent spread of resistant organisms.

Impact of Genomic Analysis on KPC-2 CPE Transmission

Genomic data further revealed that the outbreak was not solely caused by the movement of a single bacterial strain. The researchers identified an IncX3 plasmid carrying the bla_KPC-2 gene. This specific plasmid moved between K. pneumoniae and E. coli through horizontal gene transfer. Because this mechanism allows resistance to jump between different species, it makes KPC-2 CPE transmission much harder to track using culture-based methods alone. Therefore, genomic analysis is essential for identifying both clonal spread and plasmid-mediated resistance.

Furthermore, the study showed that several cases were "imported" into the hospital from other facilities. These imported strains were identical to those causing the internal outbreak. This indicates that the hospital had likely experienced undetected introductions of the pathogen well before enhanced screening protocols were implemented. For clinicians in India, where antimicrobial resistance is a growing concern, these results underscore the necessity of active surveillance and rapid molecular diagnostics in high-risk settings like ICUs and dialysis units.

Frequently Asked Questions

What is the clinical significance of the ST307 clone in this outbreak?

ST307 is a high-risk global clone of Klebsiella pneumoniae known for its high transmissibility and association with carbapenem resistance. In this outbreak, it served as the primary vehicle for clonal spread across multiple hospital wards.

How does horizontal gene transfer complicate infection control?

Horizontal gene transfer allows resistance genes, such as bla_KPC-2, to move between different bacterial species via plasmids. This means an outbreak can involve multiple types of bacteria, making it difficult to identify a single source of infection without genomic sequencing.

Why is active surveillance better than reactive screening?

Active surveillance identifies colonized patients who do not yet show symptoms. As seen in this study, reactive screening often starts too late, allowing the pathogen to establish hidden transmission networks that persist for weeks before detection.

Disclaimer: This content is for informational and educational purposes only. It does not constitute medical advice or a substitute for professional healthcare consultation. Refer to the latest local and national guidelines for clinical practice.

References

Park SH et al. Outbreak investigation and genomic analysis reveal hidden transmission networks of KPC-2-producing Enterobacterales in a South Korean hospital. Antimicrob Resist Infect Control. 2026 Feb 07. doi: 10.1186/s13756-026-01706-x. PMID: 41654982.

Indian Council of Medical Research (ICMR). Annual Report on Antimicrobial Resistance Research and Surveillance Network. 2023.

World Health Organization. Global Antimicrobial Resistance and Use Surveillance System (GLASS) Report: 2024 Revision.